Enoblituzumab, previously known as TJ-271 or MGA271, represents a innovative monoclonal targeting CD33, an surface protein found predominantly on myeloid tissues. The agent operates as an dual-action construct, at once https://www.targetmol.com/compound/enoblituzumab